Background Memantine has been used off -label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefi t on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an eff ective treatment for FTD.
Introduction
Frontotemporal lobar degeneration or frontotemporal degeneration (FTD) is a common cause of dementia in individuals who develop symptoms before age 65 years. FTD encompasses three core clinical syndromesbehavioural variant frontotemporal dementia (bvFTD), and two primary progressive aphasias (PPA): semantic dementia and progressive non-fl uent aphasia. 1 BvFTD is the most common form of the disease and features prominent social and behavioural defi cits as well as executive dysfunction. Semantic dementia often begins as aphasia, with progressive semantic knowledge loss, but also often features prominent behavioural abnormalities similar to bvFTD. 2 Progressive non-fl uent aphasia presents as a motor speech disorder with few other cognitive or behavioural impairments. No medications have been approved by the US Food and Drug Administration (FDA) to treat FTD, and only a handful of randomised, placebo-controlled trials have been done in FTD. 3 Despite the absence of effi cacy data supporting the use of drugs approved for the treatment of Alzheimer's disease, such drugs are frequently prescribed to patients with FTD off -label in the USA, with 55% of patients in a recent study 4 using either an acetylcholinesterase inhibitor or memantine.
Memantine is approved by the European Medicines Agency and the FDA for the treatment of moderate-tosevere Alzheimer's disease and has also shown benefi cial eff ects in clinical trials of vascular dementia, Parkinson'srelated dementias, and dementia of mixed causes (reviewed in Kalia and colleagues 5 ). Although the neuropathological changes and underlying neurotransmitter defi cits are diff erent in FTD than in Alzheimer's disease, a scientifi c rationale exists for the use of memantine to treat FTD. First, memantine is believed to act as a non-competitive inhibitor of NMDA receptors, which might be overactivated in various neurodegenerative diseases, including FTD. 5 Second, analyses of data from clinical trials of memantine in Alzheimer's disease showed clear benefi ts on various abnormal behaviours, as assessed by the neuropsychiatric inventory (NPI). 6 Since many of these behaviours are prominent features of FTD, memantine might also be predicted to improve these defi cits. Third, several openlabel treatment studies in bvFTD and semantic demen tia have shown symptomatic improvements with memantine treatment. 7, 8 In one of these studies, 8 we showed that initiation of memantine treatment was associated with a transient improvement in behaviour as measured by the NPI 9 in patients with bvFTD and semantic dementia. 8 Since the transient improvement in NPI scores might have been attributable to a placebo eff ect or an eff ect of memantine treatment, the present study tested the hypothesis that memantine would improve or stabilise behaviour as measured by the NPI and clinical global impression of change (CGIC) 10 compared with placebo, after 26 weeks of treatment.
Methods

Study design and participants
In this multicentre, randomised, double-blind, placebocontrolled trial, we recruited patients from nine US academic dementia research centres with expertise in the diagnosis of FTD 8 of memantine that showed a similar pattern of changes in bvFTD and semantic dementia, but not progressive non-fl uent aphasia, 8 the present study only included patients with bvFTD or semantic dementia. 1 Individuals with FTD-motor neuron disease were included if motor impairments did not interfere with study procedures. Individuals had to be aged between 40 and 80 years and have a mini-mental state examination (MMSE) score of 15 or higher at screening. To exclude cases with slowly progressive bvFTD (bvFTD phenocopy), all patients had to have a CT or MRI scan of the brain within 24 months before randomisation consistent with a diagnosis of bvFTD or semantic dementia. 11 All patients had a reliable caregiver who could accompany them to study visits. Exclusion criteria included a diagnosis of progressive non-fl uent aphasia, and use of memantine, acetylcholinesterase inhibitors, antipsychotic drugs, valproate, lithium, or benzodiazepines within 4 weeks before randomisation. Use of acetyl cholinesterase inhibitors was prohibited because of potential confounding eff ects on memantine effi cacy and reported adverse reactions in FTD. 12, 13 If behavioural symptoms became diffi cult to control after the baseline visit, individuals were allowed to take an atypical antipsychotic medication (olanzapine, quetiapine, or risperidone). Antidepressant use was allowed, if the dose had been stable for 1 month preceding randomisation. Another exclusion criterion was the evidence of disorders that preclude diagnosis of FTD. 1 Written informed consent was obtained from the patient and their caregiver in accordance with local institutional review board (IRB) regulations.
Randomisation and masking
Patients were randomly assigned to receive twice daily either memantine 10 mg or placebo (1:1). Randomisation codes were generated by an unmasked UCSF pharmacist (SF) with the Excel (Microsoft Offi ce) random number generator in blocks of two and four patients. Kits were given sequential numbers that corresponded to the randomisation key that was maintained in a secure location by the UCSF Investigational Pharmacy. When randomised, each successive participant was assigned by the electronic Clinical Trial Management System to the next numbered kit in sequence at each site. Tablets containing memantine 10 mg or placebo with no memantine (identical tablets) were packaged into kits (one per patient) of several blister packs (1 week of treatment per pack). All patients and study personnel were masked to treatment assignment.
Procedures
Every patient participated in six study visits over roughly 35 weeks. After the screening visit, a randomisation or baseline visit occurred within 35 days, during which initial study medication was dispensed. Individuals were titrated to the full dose of 10 mg memantine or placebo taken orally twice daily, by 5 mg per week, reaching the full dose at week 4. Patients returned at weeks 6, 12, and 26 (or early termination) for safety and effi cacy assessments. Additionally to the in-person visits, on weeks 3, 9, and 18, individuals received a phone call to assess adverse events and study medication compliance. After the visit on week 26, the study medication was stopped, and individuals returned for a 30-day off -drug safety assessment. Compliance was assessed by counting study medication remaining in the blister packs. We assessed all outcome measures at baseline and at week 26, with a subset of measures obtained at weeks 6 and 12. We grouped adverse events by Medical Dictionary for Regulatory Activities (MedRA) system organ class. Serious adverse events were defi ned as those leading to hospital admission or death.
Outcomes
The primary outcomes were the NPI and CGIC. The NPI is a measure that assesses 12 neuropsychiatric abnormalities that reveal severe abnormalities in FTD. 9 The CGIC is a seven point categorical scale that gives a global impression of change from baseline. Secondary effi cacy assessments included the clinical dementia rating sum of boxes (CDR-SB-FTD), with behavioural comportment, personality, and language domains added to better capture FTD-related defi cits; 14 the time to initiation of antipsychotic therapy; and a neuropsychological battery, including a California verbal learning test, category fl uency, phonemic fl uency, a 15 item Boston naming test (BNT), a modifi ed trails set-shifting task, backward digit span, and the digit symbol as previously described (data for backward digit span and modifi ed trails not shown).
14 Tertiary outcomes were the Zarit burden interview (ZBI 22), a 22 item questionnaire used to measure caregiver burden, 18 and subject weight in kg (since patients with FTD often gain weight).
Statistical analysis
We based our sample size calculation on a comparison of changes in NPI from baseline to follow-up between the memantine treatment and placebo groups using a two sample t test. We hoped to detect a medium eff ect size of half a standard deviation. 19 Standard power 
Placebo Memantine
bvFTD (n=33) Semantic dementia (n=9) All (n=42) bvFTD (n=31) Semantic dementia (n=8) All (n=39) Characteristics Men (%)* 28 (85%) 4 (44%) 32 (76%) 14 (45%) 5 (62%) 19 (49%) Age (years) 65·6 (62·8 to 68·4) 68·6 (63·4 to 73·7) 66·2 (63·8 to 68·6) 65·6 (62·7 to 68·3) 67·0 (62·5 to 71·5) 65·8 (63·5 to 68·1) Education (years) 15·4 (14·4 to 16·4) 15·0 (12·8 to 17·2) 15·3 (14·5 to 16·2) 15·7 (14·8 to 16·7) 15·8 (13·0 to 18·5) 15·7 (14·9 to 16·6) Disease duration (years) 3·5 (2·6 to 4·4) 2·8 (1·3 to 4·3) 3·3 (2·6 to 4·1) 3·0 (2·1 to 4·0) 2·8 (1·6 to 3·9) 3·0 (2·2 to 3·7) Weight (kg) 90·6 (83·4 to 97·8) 71·1 (64·9 to 77·2) 86·2 (80·0 to 92·4) 81·8 (75·3 to 88·3) 76·2 (61·4 to 90·9) 80·6 (74·9 to 86·3)
Primary outcomes
Secondary outcomes 8 ) show that a sample of 65 patients per group would provide power greater than 80% to detect this diff erence. The planned enrolment for the study was 140 participants.
We analysed primary and secondary outcomes using an intention-to-treat approach that included all patients who received at least one dose of medication and had a post-baseline effi cacy assessment. We used a repeated measures approach to assess the diff erence in changes over time in the repeated primary (NPI) and secondary outcomes between the memantine and placebo groups, that is, the time by treatment group interaction. Specifi cally, for every patient, we computed changes in outcomes between baseline and the 26-week follow-up and assessed the magnitude of the diff erence in these changes using linear regression methods. We repeated analyses using sex as a covariate. It was decided post hoc to reduce the CGIC values to "improved, no change, or worsened" because of the very few responses outside the middle three values. We compared CGIC values at week 26 using a Mann-Whitney U test. We did exploratory analyses in each FTD subtype and observed cases (patients who completed all four effi cacy visits) to investigate potential sources of bias in the intention-totreat analyses. Finally, we compared diff erences in outcome measures at individual timepoints using least squares means with a two-sample t test, and analysed diff erences in frequencies of adverse events using χ² tests. Analyses were done with SAS 9.3 (SAS Inc, Cary, NC) or Stata 12 (StataCorp, College Station, TX). This study is registered with Clinicaltrials.gov, number NCT00545974.
Role of the funding source
This was an investigator-initiated study that was designed by the authors and managed by the UCSF Memory and Aging Center Clinical Trials Program. The study was funded by Forest Research Institute (FRI), the research arm of Forest Laboratories, the company that manufactures and markets memantine for treatment of Alzheimer's Disease in the US. Additionally to funding, FRI provided memantine and matched placebo tablets to the UCSF Investigational Pharmacy, which created blister packs to improve compliance, monitored lot expiration, and resupplied sites. FRI had no role in study design, data collection, analysis or interpretation. All data were available to and the manuscript was written by the corresponding author with assistance from other authors. FRI had no role in manuscript preparation.
Results
Of the 100 patients assessed for eligibility, 81 patients (64 with bvFTD and 17 with semantic dementia) were randomly assigned to memantine (39 patients) or placebo (42 patients; fi gure 1). Five patients (two given memantine, three given placebo) discontinued treatment before the end of the study (fi gure 1). Despite randomisation, the placebo group contained more men than the memantine group (table 1; p=0·01). There were no other baseline diff erences in demographic variables, concomitant medication use, or outcome measures (table 1, appendix). 17 (44%) of 39 patients given memantine and 13 (31%) of 42 patients given placebo took 100% of the study medication (p=0·24); for the remaining patients, mean study medication compliance was 95·6% (95% CI 92·3-97·3) in the placebo group and 94·8% (93·0-98·2) in the memantine group.
In the intention-to-treat analysis, the change in total NPI or CGIC scores after 26 weeks did not diff er between the memantine and placebo groups (table 2, fi gure 2). A post-hoc adjustment for baseline sex diff erences did not alter the result (appendix). The CGIC showed that at week 26, 27 patients worsened, eight remained stable, and two improved in the memantine group, whereas 29 patients worsened, eight remained stable, and four improved in the placebo group (p=0·90; fi gure 2).
We noted no treatment eff ect on the functional outcome measures, the CDR-SB-FTD, FAQ, and TFLS (table 2) . CDR-SB-FTD scores increased similarly in both groups by 1·5 (95% CI 0·8-2·1) points over 26 weeks (fi gure 3). Performance on the FAQ and TFLS declined similarly in the placebo and memantine groups (table 2) . The memantine group displayed worse neuropsychological performance than the placebo group on tests of naming (BNT) and processing speed (digit symbol; fi gure 4, table 2). The groups did not diff er on other neuropsychological composite (MMSE and EXIT25) and individual test (letter fl uency, category fl uency, digit symbol, digits backwards, Boston naming test) scores (table 2). Consistent with the eff ects we observed on neuropsychological tests, we noted numerically more cognitive adverse events (confusion, memory loss, language disorders) in the memantine group than the placebo group (six vs one; p=0·056, table 3, appendix) whereas the opposite was true for psychiatric adverse events (eight vs 16; p=0·03). Two individuals experienced a serious adverse event in the placebo group (diverticulitis leading to hospital admission and vasovagal episode) and one individual experienced two serious adverse events in the memantine group (right-sided facial weakness and loss of consciousness, both leading to hospital admission). Serious adverse events were not judged to be related to treatment. UPDRS (table 2) and safety assessments did not diff er between groups (data not shown); appendix). Since only three patients began an antipsychotic medication during the study (appendix), time to antipsychotic use was not analysed. With respect to tertiary outcomes, treatment did not have an eff ect on caregiver burden (ZBI, p=0·13) or change in weight (data not shown).
Because we had previously observed a transient improvement in NPI scores in an open-label memantine treatment study, 8 we examined in a post-hoc analysis the diff erences in NPI scores at individual timepoints and noted a transient improvement (mean diff erence 5·9, 95% CI 4·2-7·6) at week 6 (p=0·01) that converged with changes in the placebo group at weeks 12 and 26 (p>0·30; fi gure 2).
We also investigated whether the eff ects we noted on the BNT and digit symbol tests were related to FTD subtype. When analysed separately, BNT performance was worse in both the bvFTD and semantic dementia groups after 26 weeks (appendix). On the digit symbol test, the placebo group showed a small improvement in performance after 26 weeks of treatment, whereas the memantine group worsened (MD 8·1, 95% CI 1·1-15·1, p=0·001; fi gure 4). 
Discussion
We noted no benefi t of 20 mg daily memantine treatment in FTD on either of the primary outcome measures-the NPI, or the CGIC-after 26 weeks of treatment. There was evidence of worse cognitive performance on tests of naming (BNT) and processing speed (digit symbol) associated with memantine treatment, and a suggestive increase in cognitive adverse events compared with the placebo group. However, the worse neuropsychological performance in the memantine group was not associated with a diff erence in the rate of decline in activities of daily living as measured by CDR-SB-FTD, FAQ, and TFLS. Although memantine was safe and well tolerated in patients with FTD, our results do not support a claim of benefi t for memantine treatment in FTD. Since about 30% of patients with bvFTD in the USA take memantine, 4 our fi ndings have immediate implications in public health.
Our results are similar to those from a recent 52-week randomised placebo-controlled trial 20 of memantine in 49 patients with bvFTD that also showed no benefi t on the primary outcome, the clinician's interview-based impression of change (ie, CIBICplus; similar to the CGIC) or the NPI. 20 Similar to the previous study, a major limitation of the present study was that we failed to enrol the planned number of patients, which might have limited our ability to detect a treatment eff ect. This underenrolment was due to many patients' preference to take memantine (and in many cases an acetylcholinesterase inhibitor as well) rather than participate in a clinical trial during which they risked being randomly assigned to placebo. Unfortunately, altering the enrolment criteria to allow use of these medications would have prevented us from testing our hypothesis that memantine might have benefi t in the treatment of FTD. Instead, to improve recruitment, sites stressed equipoise about the effi cacy of memantine when recruiting patients. A second limitation of the study was the small size of the semantic dementia group, which limits the generalisability of our results to this FTD syndrome. Finally, since this trial was designed, several rating scales that better capture FTD-specifi c behaviours have been developed that might have been more sensitive to potential benefi ts of memantine than those we used. 21 Despite these limitations, we believe that our study provides strong evidence that memantine is not an eff ective treatment for FTD. First, in an exploratory analysis, there was a transient improvement in NPI scores after 6 weeks of treatment that was similar in magnitude and timecourse to what we observed in a 
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Data are number of patients (%). Adverse events (all severities combined) occurring in two or more individuals in either group combined, and percent of intention-totreat population in each group. Adverse events occurring in only one individual are not shown. A complete list of adverse events is given in the appendix. previous open-label treatment study (34 patients with bvFTD and semantic dementia) 8 suggesting that the pattern of changes observed on the NPI (fi gure 2) did not arise by chance. Second, we did a study-level metaanalysis, combining 6-month CGIC data from the current study and 12-month CIBICplus data presented in the report from the previous bvFTD clinical trial, 20 for a combined total of 64 patients receiving placebo and 55 receiving memantine. This meta-analysis found no diff erence between placebo and memantine on the combined global impression (mean diff erence 0·082, 95% CI -0·18 to 0·34; p=0·553). Third, we observed worse visuomotor (digit symbol test) and naming function in the memantine group in the pre-specifi ed analyses (table 2) . Consistent with these fi ndings, the memantine group had a greater number of cognitive adverse events than did the placebo group (table 3) . Finally, the rate of decline in CDR-SB-FTD scores was identical in both groups, and numerically, FAQ scores seemed to decrease more rapidly in the memantine group at week 12 (fi gure 3), although, similar to the analysis of NPI scores at 6 weeks, this was an exploratory fi nding that should be interpreted with caution.
We found fewer psychiatric (behavioural) side-eff ects in the memantine group than the placebo group (table 3) . The simplest explanation for the divergent eff ects of memantine we noted in this study would be that memantine had a general suppressive eff ect on attention and cognition that led to less distressing behaviour as well as a reduced ability to perform visuomotor processing and lexical retrieval tasks.
Our study suggests that patients with FTD might respond diff erently to memantine than do patients with other forms of dementia, underscoring the importance of accurate diagnosis. In moderate-to-severe Alzheimer's disease, memantine has shown benefi ts on global and cognitive function alone or in combination with donepezil. 12 Although a pilot study of memantine in PPA (not diff erentiated by subtype) suggested a modest benefi t of treatment on the Western aphasia battery, 22 some forms of PPA are due to underlying Alzheimer's disease pathological changes, which could explain this fi nding. Clinical trials of memantine for vascular dementia also suggest a modest benefi t on cognition in patients with mild-to-moderate impairment. 23 Results from two clinical trials 24, 25 of memantine in Parkinson's-related dementia showed effi cacy for treatment of cognitive and behavioural symptoms. 24, 25 We speculate that the absence of benefi t of memantine treatment in FTD could indicate a diff erent pattern of neurotransmitter abnormalities in this disorder. 3 This is, to the best of our knowledge, the largest randomised placebo-controlled trial done in FTD so far (panel). In addition to the implications for the current treatment of FTD, we show that clinical trials are feasible in this disorder. Since about half of all FTD cases have underlying tau pathological changes, as in Alzheimer's disease, it has been suggested that tau-directed therapeutics might eventually be used in both disorders. 26 We showed that the rate of decline as measured by the CDR-SB-FTD was about twice as fast as has been reported for the CDR-SB in Alzheimer's disease. 27 The more rapid progression of FTD as compared with Alzheimer's disease might allow for faster clinical trials in FTD than in Alzheimer's disease to test the effi cacy of therapies targeting proteins such as tau that are common to both disorders. 21 This study provides clear evidence of a lack of effi cacy of memantine treatment for mild-to-moderate FTD, stressing the urgent need to develop more eff ective FTD therapeutics.
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Panel: Research in context
Systematic review
We searched PubMed for reports published between 1946 to November, 2012, using the following terms: "memantine" and "frontotemporal dementia", "semantic dementia", "frontotemporal lobar degeneration", "Pick's", "FTD", "FTLD", "primary progressive aphasia", "PPA", "corticobasal", or "aphasia". We included randomised, placebo-controlled trials in frontotemporal dementia (FTD) or a related disorder that involved memantine. We identifi ed one previous randomised trial in behavioural variant FTD (bvFTD) 21 and one in primary progressive aphasia (PPA; not diff erentiated by subtype). 22 We did a study-level meta-analysis, combining 6-month clinical global impression of change data from the current study and 12-month data from table 4 from the previous behavioural variant FTD clinical trial, 21 but not the primary progressive aphasia trial because it was not limited to semantic dementia, for a combined total of 64 patients in the placebo group and 55 patients in the memantine group.
Interpretation
No diff erence was noted between placebo and memantine on the combined global impression scores (mean diff erence=0·082, 95% CI -0·18 to 0·34; p=0·553, Mann-Whitney U). This study confi rms the absence of benefi t of memantine for treatment of FTD.
